March 7, 2020

Insert status update text here. Cras enim quam, ultrices a commodo vel, consectetur et nisl. Etiam ac nunc et enim dapibus sagittis sit amet vel sem. In erat diam, consectetur id iaculis vel, ultrices eu dolor.

March 3, 2020

Insert status update text here. Cras enim quam, ultrices a commodo vel, consectetur et nisl. Etiam ac nunc et enim dapibus sagittis sit amet vel sem. In erat diam, consectetur id iaculis vel, ultrices eu dolor.

Data Insights

Coronavirus Disease 2019 (COVID-19)

Sign up for updates

BACK TO COVID-19 RESPONSE HOMEPAGE

March 15, 2020 at 8:40 PM ET

Key data points for February 10th through March 12th*: 

  • During this time period, nearly 1.5 million patients across 45 states, Washington D.C. and the Virgin Islands were screened through Phreesia for risk factors of COVID-19 

  • The percent of patients reporting COVID-19 exposure risk (i.e. travel history, contact history) increased from 0.13% of patients screened in February to 0.36% in March
  • Note: During this time, the CDC expanded the definition of “geographically affected area.”
  • Using a subset of data (n= 404,694 patients) from March 2-12, 10.8% of all patients reported at least one COVID-19 symptom risk factor:
  • 7.6% of patients reported respiratory symptoms (i.e. cough and/or shortness of breath) without fever 
  • 1.2% of patients reported fever without respiratory symptoms 
  • 2.0% of patients reported both fever and respiratory symptoms
  • Of the patients who self-reported exposure risk (travel and/or contact risk) (n=3,592 of 1,466,447 from February 10-March 12), 33% report one or more symptom risk factors of COVID-19
  • This group of patients were screened via a self-reported questionnaire while checking in at practices in 40 states, DC and VI 
  • Of patients who reported travel risk only, 21% reported one or more symptoms (n=1,315) 
  • Of patients who reported contact risk only, 33% report one or more symptoms (n=1,807) 
  • Of patients who reported both travel and contact, 70% report one or more symptoms (n=470)

*Please note: This data is based on self-reported risk factors and is not representative of clinically diagnosed populations. Additionally, some states are more heavily represented than others. We will be analyzing this data on an ongoing basis to see how these trends evolve, with consideration for geographic, demographic and other factors.

It is extraordinary to see how medical groups and health systems have mobilized their COVID-19 preparedness efforts while providing care in the communities they serve. 

We are grateful to our network for joining with us to keep patients and staff safe. Toward these goals, Phreesia is sharing aggregate data from medical groups and health systems that are using our self-reported digital questionnaire to screen for COVID-19 risk factors during the intake process. This data includes patients identified for COVID-19 risk before they arrived for their appointment and upon arrival at their visit.

From February 10 to March 22, Phreesia practices screened 1.8M patients across 47 states and Washington D.C. See our Status Update from 3/15/20 for previous report of this data.

  • Using a subset of data for practices consistently asking the same questions (n= 1,015,030), the percent of patients reporting COVID-19 exposure risk (i.e. travel history, contact history) increased from 0.13% of patients screened in February to 0.61% in March. In the week of March 15-22, exposure risk was reported at 0.77%.  

  • Using a subset of data (n= 919,969 patients) from March 2-22, 10.7% of all patients reported at least one COVID-19 symptom risk factor. Across the population, increases in symptoms are not apparent.
  • 7.5% of patients reported respiratory symptoms (i.e. cough and/or shortness of breath) without fever  
  • 1.3% of patients reported fever without respiratory symptoms
  • 2.0% of patients reported both fever and respiratory symptoms
  • Of the patients who self-reported exposure risk (travel and/or contact risk) (n=5,519 of 1,015,030 from February 10-March 22), 40% report one or more symptom risk factors of COVID-19. In the week of March 16-22, 47% report one or more symptoms (n=2,659).
  • Of patients who reported travel risk only, 23% reported one or more symptoms (n=1,746). In the week of March 16-22, 26% reported one or more symptoms (n=823). 

  • Of patients who reported contact risk only, 44% report one or more symptoms (n=3,359). In the week of March 16-22, 54% report one or more symptoms (1,706). 

  • Of patients who reported both travel and contact, 81% report one or more symptoms (n=414). In the week, of March 16-22, 86% report one or more symptoms (n=130).
  • In the last 6 weeks, we’ve seen an 8x increase in the percent of patients reporting contact with a known or investigated case of COVID-19, from 0.06% for the week ending 2/16/20 to 0.53% for the week ending 3/22/20. Of patients who reported contact risk only or contact and travel risks (n = 3,773), 48% also reported one or more symptoms. In the week of March 16-22nd, 56% reported one or more symptoms (n=1,836).
  1. The number of patients is based on the unique patients who were screened each day (i.e., if Jane Doe completed a screening on February 10th and March 15th, we would indicate 2 screenings). 

  2. A significant number of practices initiated screening for self-reported risk factors each week, so data is indicative both of a changing measurement group and underlying trends.

Notes about the data:

March 25, 2020 at 5:45 PM ET

If you're interested in using our COVID-19 Screening Module, please click here.

© 2020 PhreesiaTM All rights reserved.

If you're interested in using our COVID-19 Screening Module, please click here.

April 9, 2020 at 8:30 PM ET

From February 10 to April 5th, Phreesia practices screened 2.5M patients across 47 states, Washington D.C., and the Virgin Islands. See our Status Updates from 3/15/20 and 3/22/20 for previous reports of this data.

  • Using a subset of data for practices consistently asking the same questions (n= 1.7M), the percent of patients reporting COVID-19 exposure risk (defined as either travel to an affected region or contact with a COVID-19 case) increased from 0.13% of patients in February to 0.77% in March. In the week of March 30-April 5, exposure risk rose to 2.7% from 1.2% the previous week (March 23-29).

Notes: Patients could answer “Yes” to both recent travel and contact, so the data points may not sum to the total shown on the blue line. The question regarding travel changed last week to include domestic travel (within the U.S.).

  • The percent of patients reporting COVID-19 contact risk increased from 0.06% of patients in February to 0.59% in March. In the week of March 30-April 5, contact risk rose to 1.6% from 1.1% the previous week (March 23-29). This represents a 26x increase over the first week (week ending February 16). Of patients who reported contact (n = 13K), the percent reporting one or more symptoms increased from 43% in February to 48% in March. In the week of March 30-April 5, 49% reported one or more symptoms (n=5.5K).

As we began screening all patients for symptoms in March, the percent of patients reporting at least one COVID-19 symptom risk factor dropped from 10.4% for March to 8.5% in April for week ending April 5 (n= 1.7M). This is consistent with trends reported by the CDC (ILINet) that show a decline in flu-like symptoms across the US in the last two weeks.

  • A subset of patients was asked about specific symptoms during the same time frame (1.5M):
    • 6.9% of patients reported respiratory symptoms (i.e. cough and/or shortness of breath) without fever. In the week of March 30-April 5, 6.1% of patients reported respiratory symptoms. 

    • 1.3% of patients reported fever without respiratory symptoms. In the week of March 30-April 5, 1.5% of patients reported fever. 

    • 1.5% of patients reported both fever and respiratory symptoms. In the week of March 30-April 5, 1.3% of patients reported both respiratory symptoms and fever.

April 24, 2020 at 5:30 PM ET

The COVID-19 pandemic has had a dramatic impact on ambulatory visits. To illustrate the extent of that impact, we collaborated with researchers at Harvard University and the Commonwealth Fund on a newly published report that leverages data from Phreesia's network of provider organizations. We hope that the data—which showed a nearly 60% drop in the number of visits to ambulatory practices beginning in mid-March—sheds light on the challenges that providers are facing and prompts policy changes to help alleviate them. 

Read the 
report.

Read our blog post about why we published our visit data.

Background 

Since February 10, 2020, Phreesia has collected over 4COVID-19 screenings in 47 states plus Washington D.C. and the Virgin Islands for self-reported risk factors, including symptoms and potential exposure, such as contact with known cases or travel to affected regions. The screening module has evolved over time with CDC guidelines. Starting March 2, practices using the standard module began asking all patients about symptoms, which is the focus of the data shared here. 

Results

  • Symptoms include fever and lower respiratory illness (cough and shortness of breath) for the entire study period. As CDC guidelines evolved, additional symptoms were added. See CDC for most up to date list for adults and for pediatrics

  • The most recent version of the adult screening tool can be found here and the pediatric screening tool can be found here 

  • States that are gray indicate no screening data available in those states

If the data shared is of interest to you or your organization or you want more information on our methods, please contact us at research@phreesia.com

See below for a map highlighting last week's data. Hover over individual states for the rate of symptoms in each one.

2019-2020 CDC ILI Baseline represents a mean percentage of patient visits for influenza-like illness during non-influenza weeks for the previous three seasons plus two standard deviations.

September 10, 2020 at 4:42 PM ET

Background 

Since February 10, 2020, Phreesia has collected over 19COVID-19 screenings in 49 states plus Washington D.C. and the Virgin Islands for self-reported risk factors, including symptoms and potential exposure, such as contact with known cases or travel to affected regions. The screening module has evolved over time with CDC guidelines. Starting March 2, practices using the standard module began asking all patients about symptoms, which is the focus of the data shared here. 

Results

  • Symptoms include fever and lower respiratory illness (cough and shortness of breath) for the entire study period. As CDC guidelines evolved, additional symptoms were added. See CDC for most up to date list for adults and for pediatrics

  • The most recent version of the adult screening tool can be found here and the pediatric screening tool can be found here 

  • States that are gray indicate no screening data available in those states